Search results
Showing 2656 to 2670 of 8935 results
In development Reference number: GID-TA11566 Expected publication date: 10 June 2026
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
In development Reference number: GID-TA11116 Expected publication date: 11 November 2026
Awaiting development Reference number: GID-TA11978 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 3 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 23 February 2026.
In development Reference number: GID-TA11203 Expected publication date: 29 April 2026
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]
Awaiting development Reference number: GID-TA11979 Expected publication date: TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]
In development Reference number: GID-TA11651 Expected publication date: TBC
Fertility problems: assessment and treatment - update 1 and 2
In development Reference number: GID-NG10263 Expected publication date: 31 March 2026
In development Reference number: GID-IPG10216 Expected publication date: TBC
Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma
In development Reference number: GID-HTG10153 Expected publication date: TBC
Technologies to support the rapid diagnosis of endometriosis (provisional title)
In development Reference number: GID-HTE10082 Expected publication date: TBC
Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)
Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making